Delamanid (DLM)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Brigham and Women's Hospital, Wuhan Pulmonary Hospital

Conditions

HIVTreat to TargetTreatment DurationTuberculosis, MDRTuberculosis, Pulmonary

Phase 2

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis

Active, not recruitingNCT05556746

Brigham and Women's HospitalTuberculosis, Pulmonary, HIV

Start: 2023-11-24End: 2027-01-01Updated: 2026-08-05

Phase 3

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active, not recruitingNCT03568383

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, MDR

Start: 2019-06-03End: 2027-01-11Updated: 2025-06-15

Unknown Phase

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Not yet recruitingNCT07198685

Wuhan Pulmonary HospitalTreat to Target, Treatment Duration

Start: 2025-09-30End: 2028-09-30Target: 52Updated: 2025-09-30

Related Papers

Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination.

2025-02-229 citations